Publications by authors named "Michael Fifer"

Claim this Profile
E
Effect of Aficamten Compared With Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM.
Sheila M Hegde, Xiaowen Wang, Pablo Garcia-Pavia, Stoyan Getchevski, Ahmad Masri, Michael A Fifer

J Am Coll Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multidomain, Patient-Level Analysis of the MAPLE-HCM Trial.
Andrew Wang, Pablo Garcia-Pavia, Ahmad Masri, Bela Merkely, Michael E Nassif, Michael A Fifer

J Am Coll Cardiol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial Cell-Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy.
Shogo Tamura, Keitaro Akita, Michael A Fifer, Albree Tower-Rader, Mathew S Maurer

J Am Heart Assoc· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multiple-Branch Alcohol Septal Ablation Is Associated with Reduced Cardiovascular Events: Insights from a Trans-Pacific Multicentre Registry.
Keitaro Akita, Ryota Sato, Atsushi Anzai, Rahul Sakhuja, Michael A Fifer

CJC Open· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiopulmonary exercise testing parameters in healthy athletes vs. equally fit individuals with hypertrophic cardiomyopathy.
Cliodhna McHugh, Sarah K Gustus, Bradley J Petek, Mark W Schoenike, Kevin S Boyd, Michael A Fifer

Eur J Prev Cardiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy.
Pablo Garcia-Pavia, Martin S Maron, Ahmad Masri, Bela Merkely, Michael E Nassif, Michael A Fifer

N Engl J Med· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM.
Sara Saberi, Theodore P Abraham, Lubna Choudhury, Roberto Barriales-Villa, Perry M Elliott, Michael A Fifer

JACC Heart Fail· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using machine learning.
Ree Lu, Heidi S Lumish, Kohei Hasegawa, Mathew S Maurer, Muredach P Reilly, Michael A Fifer

Eur J Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Detection of late gadolinium enhancement in patients with hypertrophic cardiomyopathy using machine learning.
Keitaro Akita, Kenichiro Suwa, Kazuto Ohno, Shepard D Weiner, Albree Tower-Rader, Michael A Fifer

Int J Cardiol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNP.
Itsuki Osawa, Keitaro Akita, Kohei Hasegawa, Michael A Fifer, Albree Tower-Rader

Circ Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Evaluation of Genetic Hypertrophic Cardiomyopathy Penetrance and Transition to Disease in an Academic Biobank.
Joseph Y Shin, Aeron M Small, Carrie L Blout Zawatsky, Michael A Fifer, Albree Tower-Rader

JACC Adv· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics.
Pablo Garcia-Pavia, Ozlem Bilen, Melissa Burroughs, Juan Pablo Costabel, Edileide de Barros Correia, Michael A Fifer

JACC Heart Fail· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Venom allergy in hypertrophic cardiomyopathy: When epinephrine could kill.
Hana B Ruran, Ashley Y Wu, Michael A Fifer, Wanda Phipatanakul, Saleh Alsulami

Ann Allergy Asthma Immunol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular Hypertrophy.
Keitaro Akita, Mathew S Maurer, Albree Tower-Rader, Michael A Fifer, Yuichi J Shimada

Circ Heart Fail· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.
Ahmad Masri, Mark V Sherrid, Theodore P Abraham, Lubna Choudhury, Pablo Garcia-Pavia, Michael A Fifer

J Card Fail· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profiling.
Heidi S Lumish, Nina Harano, Lusha W Liang, Kohei Hasegawa, Mathew S Maurer, Michael A Fifer

Europace· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Course and Treatment of Patients With Apical Aneurysms Due to Hypertrophic Cardiomyopathy.
Mark V Sherrid, Daniele Massera, Samuel Bernard, Nidhi Tripathi, Yash Patel, Michael A Fifer

JACC Adv· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep learning of echocardiography distinguishes between presence and absence of late gadolinium enhancement on cardiac magnetic resonance in patients with hypertrophic cardiomyopathy.
Keitaro Akita, Kenya Kusunose, Akihiro Haga, Taisei Shimomura, Yoshitaka Kosaka, Michael A Fifer

Echo Res Pract· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of cardiac death in patients with hypertrophic cardiomyopathy using plasma adipokine levels.
Keitaro Akita, Kohei Hasegawa, Michael A Fifer, Albree Tower-Rader, Jeeyoun Jung

Nutr Metab Cardiovasc Dis· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Signaling Pathways Associated With Prior Cardiovascular Events in Hypertrophic Cardiomyopathy.
Charlotte Lee, Lusha W Liang, Kohei Hasegawa, Mathew S Maurer, Albree Tower-Rader, Michael A Fifer

J Card Fail· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality After Alcohol Septal Ablation vs. Septal Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy.
Risako Yasuda, Itsuki Osawa, Tadahiro Goto, Kohei Hasegawa, Michael A Fifer

Circ Rep· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictors of cardiovascular implantable electronic device dependence at long-term follow-up after alcohol septal ablation in hypertrophic cardiomyopathy patients.
Weeranun D Bode, Michael F Bode, Megan Zhao, Igor Palacios, Rahul Sakhuja, Michael A Fifer

J Interv Card Electrophysiol· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of worsening heart failure in hypertrophic cardiomyopathy using plasma proteomics.
Heidi S Lumish, Lusha W Liang, Kohei Hasegawa, Mathew S Maurer, Michael A Fifer

Heart· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aficamten for Drug-Refractory Severe Obstructive Hypertrophic Cardiomyopathy in Patients Receiving Disopyramide: REDWOOD-HCM Cohort 3.
Anjali T Owens, Ahmad Masri, Theodore P Abraham, Lubna Choudhury, Florian Rader, Michael A Fifer

J Card Fail· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comprehensive Transcriptomics Profiling of MicroRNA Reveals Plasma Circulating Biomarkers of Hypertrophic Cardiomyopathy and Dysregulated Signaling Pathways.
Lusha W Liang, Kohei Hasegawa, Mathew S Maurer, Muredach P Reilly, Michael A Fifer

Circ Heart Fail· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis